Transatlantique Private Wealth LLC Buys 1,053 Shares of Johnson & Johnson $JNJ

Transatlantique Private Wealth LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 21.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,006 shares of the company’s stock after acquiring an additional 1,053 shares during the quarter. Transatlantique Private Wealth LLC’s holdings in Johnson & Johnson were worth $917,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Johnson & Johnson by 0.5% during the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after acquiring an additional 1,170,120 shares during the last quarter. Northern Trust Corp grew its stake in shares of Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after buying an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Johnson & Johnson by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after buying an additional 620,039 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Johnson & Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after buying an additional 712,181 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Johnson & Johnson by 2.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after buying an additional 448,666 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 1.4%

Shares of NYSE JNJ opened at $186.24 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market capitalization of $448.71 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 2.19 and a beta of 0.40. The stock has a 50 day moving average price of $183.43 and a 200 day moving average price of $167.96. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analyst Ratings Changes

A number of research analysts have recently commented on JNJ shares. Loop Capital set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 22nd. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Finally, JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.